Anti-Doping Night Raids: The Tour de France’s Controversial “Vampire” Strategy

Anti-doping authorities at the Tour de France have intensified their oversight of the race’s top contenders, employing early-morning, out-of-competition testing that has reignited a debate over athlete privacy and performance recovery. During the current edition of the race, medical teams—colloquially termed “vampires” within the professional cycling peloton—conducted blood extractions in the early hours of the morning, targeting the rooms of leaders including Tadej Pogačar and Jonas Vingegaard. These surprise visits, which occurred at 2:00 a.m. for Vingegaard and 5:00 a.m. for Pogačar, represent a significant departure from standard post-stage testing protocols.

The Regulatory Framework for Nocturnal Testing

The International Testing Agency (ITA) and the Union Cycliste Internationale (UCI) authorize these nocturnal interventions under specific conditions. According to current anti-doping regulations, these tests are permitted when there are “serious and specific suspicions.” In France, the legal threshold for such an intrusion is high: a judge in Paris must explicitly authorize the interruption of an athlete’s rest period. By securing judicial oversight, the ITA aims to combat the practice of “microdosing”—the administration of minute amounts of performance-enhancing substances like EPO, testosterone, or growth hormones during the night, which can be difficult to detect in standard daytime samples.

The ITA has reinforced its commitment to a clean race by planning approximately 600 samples for this year’s Tour. This includes 350 tests conducted prior to the start of the race, supplemented by advanced intelligence-gathering and longitudinal analysis of athletes’ biological passports. The objective is to deter riders from utilizing the traditional “quiet hours”—often cited as 11:00 p.m. to 6:00 a.m.—as a window to evade detection.

Physiological Impact and Ethical Concerns

The practice has drawn criticism from sports medicine professionals who argue that the timing of these tests interferes with the critical recovery period required for elite-level endurance. Dr. López Calbet, a professor of physiology, noted that the high physical demands of the Tour de France leave riders with a narrow window for rest. “Interrupting [rest] to perform a blood draw generates stress that can affect the quality of sleep,” Calbet stated. He further questioned the fairness of the protocols, noting that if such invasive measures are not applied to the entire peloton, the disparity in recovery time could inadvertently influence performance.

Dr. David Capapé, an advisor to elite athletes, expressed similar concerns regarding the infringement on personal space and recovery time. “It seems wrong to me that a cyclist’s rest is not respected,” Capapé said. “I think that between 10:00 p.m. and 8:00 a.m., they should not be disturbed. It seems like a matter of common sense.”

The Legacy of Microdosing Concerns

The move toward nocturnal testing is largely a response to long-standing fears regarding sophisticated doping methods. The late Victor Conte, a central figure in the BALCO scandal, frequently claimed that the absence of overnight testing provided a loophole for riders to use substances that would be cleared from their systems by the following morning. While Conte’s involvement in doping programs made his character controversial, his technical observations on microdosing have influenced the evolution of modern anti-doping strategies. The ITA’s current approach suggests that authorities are prioritizing the elimination of these overnight gaps, regardless of the discomfort caused to the riders.

Athlete Reactions and the Path Forward

For the athletes, the experience of a 4:00 a.m. or 5:00 a.m. awakening has been a source of frustration. Tadej Pogačar and Jonas Vingegaard, who have both been subject to hundreds of tests throughout their careers, have navigated these incidents with a mix of professional resignation and clear annoyance. The disruption of sleep, coupled with the logistical challenges of the race, highlights the tension between the pursuit of a “clean” sport and the physiological realities of professional cycling.

Despite the criticism, the absence of recent positive tests among the race leaders is often cited by officials as evidence that the current system is working, even if it does little to dampen the cynicism of observers who believe that doping technology remains in a constant race against detection. The last high-profile anti-doping violation at the Tour occurred in 2022, when Nairo Quintana was disqualified after testing positive for tramadol. As the Tour de France continues, the presence of the “vampires” serves as a reminder that the surveillance of the peloton has expanded beyond the finish line, extending into the quiet hours of the night.

The next official updates regarding race results and testing statistics are expected to be provided by the ITA and race organizers as the competition progresses toward the final stage in Paris.